Member Rate applies for MassBio Member Company, Other State Bioscience Association Member Company, MassCONNECT Company, or Unemployed Individual

Description

Business of Biotech 101 explores the business considerations that drive company strategies. Participants are provided with an overview of how the industry works, why it works the way it does, and how the industry may change in the years ahead. For those considering careers in the biopharma space or transitioning from the science and technical aspects of the industry to the business side, this course delivers a sound, basic understanding of the “business of biotech”. Students will be provided foundational information about the BioPharma industry and regulation via instruction, storytelling, and breakout group discussions. Industry ethics will be discussed, with emphasis on historical precedents. We will explore the decision-making process by touching on relevant topics such as market share, phases of development, patient population, and safety profile. Guest speakers will be invited to represent specific considerations and to showcase their roles and experiences. We will embark upon a high-level overview of Research and Development, including pre-clinical through market approval.

Session 1:
Origins of the Biotech Industry: a Brief History
Addressing Unmet Medical Need
Biotechnology techniques used for therapeutics development
Biotech Entrepreneurship
Business Models of the Sector and Industries within

Session 2:
Preclinical
Clinical Development
Creating Barriers to Entry: Market Exclusivity

Session 3
Patents
Early Stage Financing

Instructor

John Tagliamonte
Chief Executive Officer, Mellitus

John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies.  As the first Entrepreneur-in-Residence with the Mass Bio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu.  Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard.  He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad.  Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.